etherna blog

Unlocking mRNA Therapeutics: etherna's Blueprint for Ultra-Pure mRNA

media@etherna.be (etherna marketing team) — Mon, 31 Aug 2026 09:13:44 GMT

Success in mRNA therapeutics starts long before the first dose reaches a patient. It begins at the molecular level with intelligent construct design.

At etherna, from construct designing to optimized manufacturing processes are the strategic foundations of every mRNA therapeutic. Our design and upstream first approach deliver ultra-pure, high-expressing mRNA, built for scale and impact.

We believe that the quality of the final mRNA product is intrinsically linked to the precision and innovation behind its design. We meet customer expectations collaboratively by engineering custom constructs to consistently maximizing therapeutic potential from the very start.

💡 Beyond the Blueprint: Codon Optimization

It's not just about making the mRNA sequence but making it "translation-friendly" for the target cell. Our proprietary sequence optimization algorithm enhances the translation efficiency of the gene of interest by changing compatible codons.

Why sequence optimisation??

Improved RNA integrity ensures that the full, functional genetic message is present.
Enhanced expression means more of the desired therapeutic protein is produced from the same amount of mRNA.

The result is a cleaner, more functional mRNA that performs efficiently, a clear advantage in both discovery and clinical-stage developments.

UTR Optimization: Superior Performance, Proven Results

At etherna, we leverage our extensive research to offer a high-throughput screening platform of our proprietary UTR library. This allows us to identify the optimal UTR combinations tailored to maximize gene expression specifically in your cell type of interest, ensuring enhanced performance and efficiency in your applications.

Our recent in vivo studies, following intramuscular (IM) administration, show the superior capabilities of etherna's proprietary UTRs:

Boost in Protein Expression: When evaluating luciferase (fLuc) mRNA-LNPs, our UTRs consistently delivered a substantially higher level of luminescence compared to benchmark UTRs, both at 24 and 48 hours. This translates to significantly more protein being produced in the body, a critical factor for therapeutic efficacy (Image 1).
Antibody Titers: The real game-changer lies in immune response. In studies with HA mRNA, etherna's UTRs generated up to a 10-fold increase in anti-HA IgG titers for HA mRNA and 4-fold higher anti-Spike IgG titers for spike mRNA, compared to controls, demonstrating a profound impact on immunogenicity (Image 2).

Crafting the optimal UTR combination is key to unlocking mRNA's full potential, ensuring robust and sustained protein production.

Image 1: FLuc mRNA-LNPs

Image 2: HA mRNA or Spike mRNA-LNPs

🏭 Design to Delivery: A Manufacturing Strategy That Begins Upstream

Our commitment to quality doesn’t end with design. We’ve engineered an upstream-first manufacturing process approach that lays the groundwork for high-yield, ultra-pure mRNA minimizing the purification burden downstream.

During in vitro transcription (IVT), we precisely optimize enzyme ratios, reaction times, and temperature conditions to reduce impurities like double-stranded RNA (dsRNA) and incomplete transcripts.

Here’s how upstream optimization helps streamline the entire mRNA manufacturing process:

Reduces byproduct formation: Optimized IVT conditions limit the creation of dsRNA and incomplete mRNA fragments from the start
Enables predictable product profiles: A cleaner upstream output empowers downstream teams to execute tailored purification processes, enhancing the effective removal of residual impurities
Eliminates immune activation: With extremely low levels of residual dsRNA, our mRNA shows no signs of triggering innate immune responses

etherna can deliver scalable mRNA production with consistent quality from research-grade batches to GMP manufacturing. Whether you’re working at the milligram or multi-gram level, our platform ensures purity, potency, and reproducibility.

📊 Results You Can See and Trust

Our commitment to purity and performance is measurable. In a recent benchmark study of etherna’s off-the-shelf reporter mRNA, our constructs contain exceptionally lower levels of double-stranded RNA (dsRNA) – a critical factor in ensuring safety and efficacy in multiple therapeutic applications. (Discover our high-quality, off-the-shelf reporter mRNAs)

Why does this matter?

High mRNA integrity ensures efficient protein translation, stability, and reproducible performance in therapeutic and research applications
Testing also shows our mRNA triggers the lowest innate immune activation compared to other manufacturers

These results reflect the strength of our design principles and the reliability of our integrated process. (Read for more information)

💰 Better by Design: How etherna’s pure mRNA Lowers the Cost of Innovation

1. Lower doses

Sequence engineered codons, UTRs, and optimized upstream processes lead to more achieving desired biological responses with less mRNA.

Cost benefit: Reduces raw material usage per vial/injection, a major cost factor.

2. Fewer Development Iterations

High-quality mRNA constructs that express robustly and avoid immune activation are less likely to fail in preclinical or early clinical stages.

Cost benefit: Saves money on repeated animal studies, analytical testing, and regulatory delays by reducing rounds of redesign, reformulation, or retesting.

3. Scalability without surprises

Consistently manufactured, well-designed mRNA allows for smooth process scale-up without unexpected failures or expensive revalidations.

Cost benefit: Reduces cost and time associated with tech transfer and enables predictable, scalable production from bench to bedside.

Bottom Line:

From intelligent design to optimized processes, we are committed to delivering quality RNA to bring your therapy to improve patient’s lives. etherna isn't just a CDMO. We are your mRNA-LNP partners, with the tools, science, expertise and scale to bring your therapy to life.

Let’s Advance Nucleic Acid Therapeutics - Together

If you're passionate about mRNA-LNP innovation, manufacturing excellence, and therapeutic impact. Let’s connect.

✅ Check out our articles for more information

Share with us: What’s your biggest challenge with mRNA design or production?

Navigating Nucleic Acid Therapy Development: Partnering with etherna

media@etherna.be (etherna marketing team) — Thu, 30 Jul 2026 12:57:35 GMT

Starting a nucleic acid therapeutic or vaccine programme is undeniably a challenging and technically complex journey, but one that is deeply rewarding from both a scientific and patient-impact perspective.

The science is young, the variables are many, and choices made in the initial stages shape everything that follows. For teams considering a technology partnership, the most practical question is often the simplest one: What does this entail in practice?

This article walks through the full arc of a technology partnership with etherna, from the initial conversation through to clinical studies.

Stage 1: Mutual Discovery

The first conversation with etherna is a scientific scoping discussion.

Before any agreement is in place, our team works to understand the fundamentals of your programme: the target and its mode of action, the indication, the payload type, the intended route of administration, and the stage you are at. This is where we determine whether our platforms are the right fit, early and direct feedback helps to prevent misaligned expectations and unnecessary downstream risk.

For most programmes, the key questions at this stage focus on payload and its delivery. The payload’s type and mode of action define the required delivery profile, driving decisions around lipid nanoparticle biodistribution, immunogenicity, repeat‑dosing feasibility, and the stability and encapsulation characteristics needed for success.

This stage typically takes one to two meetings. The outcome is a shared understanding of the scientific challenge and a clear view of which etherna platforms are relevant to your programme.

Stage 2: Feasibility and Platform Selection

Once a fit is established, the partnership formally begins with a feasibility phase. This is where scientific hypotheses are tested and the most appropriate LNP platform is identified for your application.

etherna’s platform portfolio includes six distinct LNP systems. These cover liver-targeted intravenous delivery, hematopoietic stem cell delivery, T‑cell delivery, tolerizing formulations, intramuscular vaccine delivery, and intratumoral administration. Each platform has a defined biodistribution profile, immune behaviour, and payload compatibility. Selecting the appropriate LNP candidate involves screening payload performance and/or tissue-specific delivery across LNP formulations rationally selected based on the differential properties of our proprietary ionizable lipids.

During feasibility, etherna scientists work closely with your team to define the formulation strategy, scientific criteria, and decision points relevant to your programme. etherna provides platform insight, comparative guidance, and interpretation frameworks, while experimental execution remains with the sponsor team. The outcome is the identification of a lead LNP candidate, supported by shared data and a clear, jointly agreed rationale for progressing the programme.

Typical duration: two to six months, depending on programme complexity and payload availability.

Stage 3: Lead Platform Optimisation

With a lead LNP candidate selected, the focus shifts to optimising performance for the specific payload and indication. This is where customisation delivers its greatest value.

Optimisation runs across several dimensions in parallel: optimization of ionizable lipid chemistry leveraging a library of more than 2,500 proprietary molecules, adjustment of LNP composition ratios, and evaluation of conjugation strategies for active targeting when required.

Throughout this stage, etherna provides the experimental infrastructure and delivery expertise, while your team brings disease understanding, target biology, and clinical intent. It is a genuine co‑development model, with joint decision‑making driven by data.

The outcome is a defined LNP formulation with characterised performance across the parameters that matter most, including expression level, biodistribution, tolerability, and stability.

Typical duration: three to six months

Stage 4: Preclinical Development and Clinical Studies

Once the lead LNP formulation is locked, the programme transitions into formal preclinical development. At this point, etherna’s integrated manufacturing capability becomes central.

LNP formulation expertise and GMP manufacturing activities are tightly coordinated in Belgium, with the transition from research‑grade material to GMP production actively managed internally, combining in-house mRNA GMP manufacturing (if required) and externally executed LNP GMP manufacturing. This integrated setup minimises handoffs, reduces reformulation risk, and preserves process knowledge around how each specific LNP behaves. Where additional specialised assays or studies are required, etherna works with qualified third‑party vendors, while retaining scientific oversight and integration of the resulting data.

By the end of this stage, the programme has a characterised, GMP‑manufactured LNP‑RNA product candidate, supported by an integrated data package and ready to advance into clinical development.

Typical duration: eight to twelve months, depending on regulatory pathway and study design.

What Makes This Model Different?

Many nucleic acid-based therapy programmes rely on multiple vendors across the development journey. One partner for sequence design, another for LNP formulation, and a third for GMP manufacturing. Each handoff introduces risk, reformulation, timeline delays, loss of process knowledge, and gaps in accountability.

etherna operates an integrated model that spans RNA chemistry (if required), LNP formulation, and GMP manufacturing. A programme that begins with platform selection reaches IND with the same scientific team, the same proprietary materials, and a manufacturing process designed alongside the formulation rather than adapted after the fact.

For programmes where speed and risk reduction matter, this integration is a strategic advantage, not a convenience.

Is a Partnership with etherna Right for Your Programme?

A technology partnership with etherna works best for teams that meet most of the following criteria. You are working with nucleic acid payloads and require a differentiated delivery solution. You are in early discovery through late preclinical development. You are looking for a science‑led partner rather than a transactional manufacturer. And biodistribution, targeting, or immune modulation is a central technical challenge in your programme.

If that reflects your situation, the right next step is a scientific conversation with our team.

Speak with our experts →

Frequently Asked Questions

At what stage of development should we approach etherna?

etherna supports programmes from early discovery through IND and beyond. Early engagement provides the greatest opportunity to influence platform selection and RNA design. We also work with teams reformulating existing programmes or addressing manufacturing challenges mid‑development.

How long does it typically take to go from first conversation to IND?

A typical partnership spans twelve to eighteen months, progressing through feasibility, lead optimisation, and preclinical development. Programmes with well‑defined payloads and clear target profiles often move faster.

What does co‑development mean in practice?

etherna contributes platform expertise, proprietary lipid libraries, experimental infrastructure, and manufacturing capability. Your team contributes disease knowledge, target biology, and programme strategy. Scientific decisions are made jointly, guided by data at every stage.

Can etherna support programmes beyond mRNA?

Yes. etherna’s LNP platforms support multiple nucleic acid payloads, including DNA, circular RNA, saRNA, tRNA, siRNA, and antisense oligonucleotides.

Does etherna handle GMP manufacturing, or is this a separate engagement?

GMP manufacturing is an integrated part of etherna’s offering, including in-house mRNA GMP manufacturing. Core LNP GMP activities are managed in‑house, while LNP GMP manufacturing is performed with carefully selected external manufacturing partners. etherna works in close alignment with these vendors, maintaining scientific, technical, and quality oversight throughout the process to ensure consistency, robustness, and the highest product quality from development through clinical supply.

etherna is a pioneer in nucleic acid‑based medicine development, combining deep delivery science with integrated manufacturing expertise headquartered in Niel, Belgium. etherna partners with innovators to translate Nucleic acid-based therapies from concept to the clinic. To discuss your programme, Contact our team.